SALMETEROL 50mcg. IP + FLUTICASONE PROPIONATE 250mcg. IP

A fixed-dose combination inhalation agent that treats wheezing, shortness of breath, coughing, and chest tightness caused by chronic obstructive pulmonary disease Improves lung function and asthma symptoms to a greater extent than monotherapy with inhaled corticosteroids such as fluticasone propionate. (Kate McKeage, 2009) Relaxes and opens air passages in the lungs, making breathing easier. A well-tolerated and effective agent in achieving asthma control. (M Aubier, 1999) An effective, well-tolerated, and cost-effective option for the maintenance treatment of individuals with asthma. (Neil A Reynolds, 2005) Represents a cost-effective treatment option in patients with asthma not controlled with inhaled corticosteroid therapy. (Katherine A Lyseng-Williamson, 2003) More effective than salmeterol at reducing the rate of moderate to severe exacerbations over 1 year. (Gary T Ferguson, 2008) Significantly more effective in improving morning peak expiratory flow and asthma symptoms and decreases exacerbation rates than oral montelukast. (Jorge Maspero, 2008) Produces an improvement in respiratory symptoms and morning peak expiratory flow values in patients with moderate to severe COPD. (Ulrik, 1995) Reduces the levels of inflammatory factors and improves symptoms of chronic obstructive pulmonary diseases. (Li Yang, 2011) Shows greater control of lung function and symptoms than ipratropium bromide/albuterol bronchodilator therapy, in patients with chronic obstructive pulmonary diseases. (James F Donohue, 2004) Significantly more effective than budesonide in ameliorating pulmonary function and reducing symptoms. (Nan Shan Zhong, 2004) Reduces the use of rescue medication in asthmatic patients who are poorly controlled on inhaled corticosteroids. (Nan Shan Zhong, 2004)